Ardelyx remains challenged by Xphozah’s failed Medicare reimbursement appeal and persistently high SG&A spend. Learn why ARDX ...
Shares of Arcturus Therapeutics gained after the company said it would work with Thermo Fisher Scientific to advance a therapy for cystic fibrosis. The stock rose 5.8% to $7.29 in premarket trading ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results